Bedfordshire, Luton and Milton Keynes Area Prescribing Committee

Ref: APC Bulletin 261
Bulletin Date: 01/03/18
Review Date: March 2021

Bulletin 261 : Tolvaptan (Samsca® Brand) tablets for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in patients not requiring chemotherapy

Formulary Status - RED

Hospital Only
To be prescribed by a specialist and supplied from secondary care ONLY throughout treatment.

APC Recommendations:

To support the East of England Priorities Advisory Committee (PAC) Guidance and recommendations (See attached EoEPAC bulletin) with the additional caveat that ‘secondary care’ (referred to in the EoEPAC recommendations) includes hospices.

View Document

Please use the search box to search the whole site if you can't find what you're looking for:

Bedfordshire, Luton and Milton Keynes Area Prescribing Committee

Bulletin 261 : Tolvaptan (Samsca® Brand) tablets for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in patients not requiring chemotherapy

Formulary Status - RED

Hospital OnlyTo be prescribed by a specialist and supplied from secondary care ONLY throughout treatment.

APC Recommendations:

Hospital Only
To be prescribed by a specialist and supplied from secondary care ONLY throughout treatment.